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Adipocyte fatty acid-binding protein levels are associated with
left ventricular diastolic dysfunction in morbidly obese subjects
A Baessler1,6, V Lamounier-Zepter2,6, S Fenk1, C Strack1, C Lahmann3, T Loew1, G Schmitz4, M Blu¨her5, SR Bornstein2 and M Fischer1
OBJECTIVES: This study aimed to examine the association of adipocyte fatty acid-binding protein (FABP4) levels with left
ventricular diastolic dysfunction (LVDD) in obese subjects with varying degrees of the metabolic syndrome (MetS).
METHODS: Fifty morbidly obese subjects with LVDD were selected at random and matched by age (±5 years) and sex with
50 morbidly obese with normal left ventricular (LV) function. In addition, 24 healthy lean subjects were included as controls.
RESULTS: Median FABP4 levels (interquartile range) in obese subjects with LVDD were signiﬁcantly higher (42 ngml 1 (32–53))
than in obese with normal LV function (24 ngml 1 (36–43), P¼ 0.036), and in normal weight controls (13 ngml 1 (10–20),
Po0.0001). Increasing FABP4 tertiles were signiﬁcantly associated with parameters of LVDD, the number of LVDD components,
physical performance and epicardial fat thickness. In multivariate regression analysis adjusting for age, sex and adiposity, FABP4
levels remained signiﬁcantly associated with parameters of diastolic function. The association of FABP4 levels with LVDD was mainly
observed in subjects with metabolic complications, but not in metabolically healthy obese.
CONCLUSIONS: FABP4 levels are signiﬁcantly associated with LVDD in obese subjects, when the MetS is present. Thus, FABP4 may
be a link between obesity and cardiometabolic disorders.
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INTRODUCTION
Adipocyte fatty acid-binding protein (FABP4, also termed ‘A-FABP’)
is a member of the cytosolic fatty acid-binding protein family and
is highly expressed in adipose tissue by means of adipocytes and
macrophages.1,2 The biological function of FABP4 is the binding
and trafﬁcking of fatty acids from cell membranes to intracellular
targets.3 Recent studies support a novel role of FABP4
independent of its function as a carrier protein.4 Several animal-
based and clinical studies have demonstrated that FABP4 has an
important role in obesity-related insulin resistance, inﬂammation
and atherosclerosis, suggesting FABP4 as a potential link between
obesity and cardiometabolic diseases.5–9 In experimental animal
models, FABP4 deﬁciency protects against the development of
diabetes and atherosclerosis in both genetic and dietary forms of
obesity.5,10 Furthermore, humans with a functional genetic variant
of the FABP4 gene, resulting in reduced adipose tissue expression
of FABP4, have a signiﬁcantly reduced risk for type 2 diabetes and
coronary artery disease.6
FABP4 has also been shown to directly suppress cardiomyocyte
contraction in vitro,11 suggesting a pathogenetic role of FABP4 in
heart dysfunction. In accordance with these in vitro data, serum
concentrations of FABP4 are elevated in heart failure (HF) patients and
are associated with the incidence and severity of HF.12,13 Moreover,
FABP4 serum levels are associated with the parameters of left
ventricular remodeling and function in healthy obese women.14–17
These data imply that FABP4 may have a causal role in the
pathogenesis of HF, particularly in obese subjects with metabolic
alterations.
Left ventricular diastolic dysfunction (LVDD) has been described
as an early sign of obese and diabetic cardiomyopathy preceding
the systolic damage. Indeed, LVDD is a well-recognized conse-
quence of obesity that can progressively lead to HF, and is linked
to increased mortality.14–16 Interestingly, our previous data have
shown direct depressive effects from human adipocytes factors on
both contraction and relaxation rates in isolated perfused rat
hearts.18 These in vitro functional changes are similar to those
observed in the obese subjects.
Although there is evidence about the association of FABP4
serum levels with the incidence and prevalence of HF, FABP4
levels have not been correlated to parameters of LVDD so far.
Thus, in the present study, we hypothesized that serum FABP4 is a
novel marker for LVDD in morbidly obese subjects with varying
degrees of metabolic syndrome (MetS).
SUBJECTS AND METHODS
Study population
Subjects were participants of the ‘Obesity weight reduction and
remodeling study’, a prospective longitudinal study evaluating excessive
body fat for its pathogenic potential in terms of cardiometabolic diseases
and assessing the effects of considerable weight reduction on the
interactions in systems biology.
Obese patients intending to participate in a weight reduction program
were offered enrollment in our research study before the start of the
program. Patients were eligible for enrollment if they were 18–65 years old,
with a body mass index (BMI)430 kgm 2 and a constant body weight in
the last 3 months, and if they signed the declaration of consent. Exclusion
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criteria were described elsewhere.19,20 Healthy normal weight control
subjects (BMI 20–24.9 kgm 2) of similar age and gender distribution were
also included. They were recruited by ﬂyers and advertisements. MetS was
deﬁned according to the NCEP ATPIII criteria: abdominal obesity (waist
circumferenceX102 cm for men,X88 cm for women), raised triglycerides
(X150mgdl 1), reduced HDL cholesterol (o40mgdl 1 for men,
p50mgdl 1 for women), elevated blood pressure (X130/X85mmHg)
and impaired fasting glucose (X110mgdl 1).21 The study was approved
by the local Ethics Committee.
For the present study, 50 morbidly obese subjects with LVDD were
selected at random and matched by age (±5 years) and sex with 50
morbidly obese subjects with normal left ventricular (LV) function. From
the latter, four subjects were excluded due to incomplete data. In addition,
24 healthy normal weight control subjects served as controls.
Echocardiography
Echocardiography was performed using a standard ultrasound system
(Philips iE33, Philips Medical Systems, Hamburg, Germany). LV ejection
fraction (EF) was measured on the basis of the modiﬁed biplane Simpson’s
method. The following parameters were measured according to previous
ASE guidelines:22 parasternal long-axis diameter and apical four-chamber
area. Measurements were done just before mitral valve opening. LV mass
index was calculated by the Devereux formula indexed to the body surface
area. Conventional transmitral ﬂow was measured with pw-Doppler. Early
(E), late atrial (A) transmitral peak ﬂow velocities, their ratio (E/A) and
deceleration time (DT) of the early transmitral ﬂow velocity were measured
and three consecutive beats were averaged. Pulsed-wave tissue Doppler
imaging was performed at the junction of the lateral mitral annulus and
three consecutive beats were averaged. Early diastolic velocities (e0 lateral)
were recorded. Ratios of E/e0 lateral were calculated. Moreover, we
determined the isovolumetric relaxation time, the difference between
measured duration of reversed pulmonary vein atrial systole ﬂow (Ard) and
duration of mitral A wave ﬂow (Ad), as well as the ratio of pulmonary
vein systolic (S) and diastolic (D) ﬂow velocities by pw-Doppler
measurements.23
We measured the agreement between E/e0 measurements of two expert
cardiologists in obese study participants by the use of the concordance
correlation coefﬁcient (CCC). The CCC combines a measure for precision
and a measure for accuracy to evaluate reproducibility and inter-rater
reliability.24 The CCC for 20 duplicate E/e0 measurements of the two expert
sonographers was 0.976±0.014 (Po0.0001).
Deﬁnition of diastolic dysfunction
Diastolic dysfunction was deﬁned as fulﬁlment of the following criteria:
(1) a preserved systolic LV function (EF450%) and (2) presence of at least
two of the following criteria consistent with abnormal LV relaxation,
ﬁlling, diastolic distensibility or diastolic stiffness:23 E/e0 lat.48, E/Ao0.8
and DT4200ms 1 or E/A42 and DTo160ms 1, e0 lat.o10 cm s 1,
e0/a0o0.9, SoD in pulmonary venous ﬂow, Ard-Ad40ms 1,
LV mass4149 gm 2 (in men), 4122 gm 2 (in women) or an enlarged
left atrial (LA) size (LA area (4 CH planimetry)) 420 cm2 or LA diameter
(PLAX)448mm). In contrast, subjects with a normal lateral e0 X10 cm s 1
together with a normal LA size were classiﬁed as having normal LV
function according to ASE 2009 consensus criteria.22
Anthropometric and metabolic evaluation
Body composition was determined by bioelectrical impedance analysis
using Nutriguard-Impedance analysis apparatus (Data Input GmbH,
Darmstadt, Germany). Body weight, height, waist and hip circumference,
and blood pressure were measured in a standardized manner.
Serum samples were collected after a 12h overnight fast and immediately
stored at  70 1C. The samples had not been thawed before the present
measurements. FABP4 concentrations were determined by enzyme immuno-
metric assay (EIA, Cayman Chemical, Ann Arbor, MI, USA) with an intra-assay
coefﬁcient of variation of 3.9% and an inter-assay coefﬁcient of variation of
5.1%. The GDF-15 concentrations were determined by enzyme-linked
immunosorbent assay (Quantikine, R&D Systems Europe, Wiesbaden,
Germany). The NT-proBNP levels were determined by a standard chemilu-
minescence immunoassay (Roche Diagnostics, Mannheim, Germany). Fasting
glucose, insulin, blood lipids and high-sensitivity C-reactive protein were
determined by standard methods in the certiﬁed clinical chemistry laboratory
of the University Hospital. Insulin resistance was estimated by homeostasis
model assessment index (HOMA-IR) by the formula: (fasting insulin (mUml 1)
 fasting glucose (mmol l 1)/22.5).
6min-walk test
Patients were instructed to walk from end to end in an enclosed corridor,
covering as much ground as they could during 6min. The distance walked
was read using an electronic meter counter, and the maximum heart rate
was immediately measured.
Statistical analysis
Categorical variables were compared using the Fisher’s exact test.
Continuous variables were compared using one-way analysis of variance
for normally distributed variables (if signiﬁcant, the Student’s t-test for
the comparison of two groups or the Tukey–Kramer post hoc test for
multiple pairwise comparisons were used). For non-normally distributed
variables we used the Kruskal–Wallis test, and the Dwass–Steel post hoc
test was used to make all possible pairwise comparisons, accounting for
multiple testing. Association between echocardiographic parameters and
tertiles of FABP4 levels were analyzed with one-way analysis of variance.
Statistical signiﬁcance was considered at the 0.05 level. All analyses were
conducted using JMP Version 9 (SAS Institute Inc., Cary, NC, USA) and
STATA 8 (Statacorp., College Station, TX, USA).
RESULTS
The clinical characteristics of obese subjects with LVDD and with
normal LV function and lean controls are displayed in (Table 1).
Subjects with LVDD were signiﬁcantly more obese and had a
higher systolic blood pressure than obese subjects with normal LV
function. Nevertheless, metabolic parameters such as fasting
glucose, insulin and HOMA-IR levels, as well as blood lipids,
inﬂammatory markers and adipokines were comparable in obese
subjects with and without LVDD.
The corresponding echocardiographic characteristics are shown
in (Table 2). By deﬁnition, obese subjects with LVDD presented
with higher features of LV hypertrophy such as septal thickness,
relative wall thickness, LV mass and left atrial size, as well as higher
E/e0, Ard-Ad values and isovolumetric relaxation time than obese
subjects without LVDD. Moreover, lower e0 and e0/a0 were found in
the group of LVDD obese. In contrast, there was no difference with
respect to EF and end-systolic/end-diastolic LV diameters. Obese
subjects with LVDD showed a decreased physical performance in
comparison with obese subjects with normal LV function, as
observed by a shortened 6-min walk distance.
With respect to HF markers, GDF-15 and FABP4 levels were
signiﬁcantly higher in the obese with LVDD than without LVDD
(Table 2).
In Figure 1 the performance of FABP4 serum levels is
demonstrated for a variety of echocardiographic parameters of
diastolic function. FABP4 levels have been categorized into tertiles
of parameter distributions. There was a signiﬁcant correlation
between increasing tertiles of FABP4 with epicardial fat thickness,
decreasing e0, increasing E/e0 ﬁlling index, LA size, the number of
LVDD criteria, as well as decreasing 6-min walking distance. Similar
ﬁndings could be observed for LV mass (P for trendo0.0001), E/A
ratio (measured by pw Doppler, P for trend 0.033), e0/a0 ratio
(measured by tissue Doppler, P for trend 0.009), isovolumetric
relaxation time (P for trend 0.043) and GDF-15 plasma levels (P for
trend 0.002).
FABP4 serum levels increased by the number of MetS
components (from 29.9±4.2 in obese subjects with no additional
MetS component to 51±4.0 ngml 1 in subjects with more than
three MetS components, Po0.0001). In Figure 2 FABP4 serum
levels are depicted in obese subjects with or without LVDD
stratiﬁcation according to the existence of the MetS. FABP4 levels
were comparable in metabolically healthy obese subjects with and
without LVDD. However, when the MetS was present, FABP4 levels
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were signiﬁcantly higher in the obese with LVDD than in the MetS
obese with normal LV function.
Multivariate-adjusted regression analysis of the relationship of
different diastolic function parameters with FABP4 serum levels
are shown in (Table 3). When accounting for age, sex and visceral
obesity (waist-to-hip ratio) there was a signiﬁcant relationship of
FABP4 levels with almost all parameters of diastolic function, with
the exception of NT-proBNP levels. The highest beta weights were
observed for the association of FABP4 levels with LA size and E/e0
ﬁlling index. However, additional adjustment for the existence of
the MetS, deﬁned according to NCEP ATPIII, reduced the beta
estimates and weakened the association with LVDD parameters.
DISCUSSION
The results of the present study indicate that obesity with LVDD is
connected with higher FABP4 levels, particularly when MetS is
present.
FABP4 is a small lipid-binding protein, highly expressed in
adipose tissue and also expressed in macrophages. It is one of the
most abundant cytoplasmic proteins in mature adipocytes with a
main function of intracellular binding and trafﬁcking of lipid
ligands. However, signiﬁcant amounts of this protein are found in
the circulation and the levels of circulating FABP4 are directly
associated with, and even predict the development of the
MetS.1,25 Although its biological role is not fully understood, its
function has been correlated to insulin resistance, lipid
metabolism, inﬂammation and atherosclerosis.26 Moreover,
increased FABP4 levels have been associated with increased
frequencies of cardiovascular events such as acute coronary
syndromes, coronary artery disease mortality and congestive
HF.17,27 Indeed, serum FABP4 levels are increasing progressively
with the New York Heart Association (NYHA) functional class, and
are positively correlated with NT-proBNP, echocardiographic
parameters of LV geometry and systolic dysfunction in HF
patients.12,13,17,28
Owing to the increasing prevalence of risk factors such as
obesity and the MetS, the prevalence of HF is increasing. LVDD is a
common pathophysiological mechanism underlying this disorder,
with preclinical LVDD believed to be a precursor of HF with
preserved EF.29,30 In fact, LVDD is a common ﬁnding in the general
population and even asymptomatic LVDD is a powerful and
independent risk for increased mortality.31
Our results indicate that FABP4 levels are also related to
parameters of LVDD in the morbidly obese. However, the
association between LVDD and FABP4 levels was weakened when
adjusting for the existence of the MetS. These ﬁndings bring to
question whether FABP4 is involved in causative links between
adiposity, the MetS and related cardiovascular complications, such
as LVDD, and ultimately HF.
Although there is ample evidence that FABP4 serum levels
correlate with metabolic and inﬂammatory risk factors and
independently predict the presence of the MetS,32,33 the relation
of FABP4 with LVDD might be found only as an indirect
association, as the MetS comprises LVDD risk factors such as
Table 1. Clinical data in normal weight controls, obese without and
with LVDD
Control Obese, no
LVDD
Obese, LVDD
N 24 46 50
Age (years) 43±11 42±9 44±8
Sex (% f) 63 72 66
BMI (kgm 2) 22.9±2.3 36.6±7.9** 43.0±10.8**,ww
Waist (cm) 79±8 112±20** 125±24**,ww
WHR 0.81±0.02 0.88±0.01** 0.92±0.01**
Fatmass (kg) 16±4 45±13** 58±24**,ww
Lean mass (kg) 50±9 61±17* 71±22**,w
Systolic BP (mmHg) 125±13 136±6* 147±22**,w
Diastolic BP (mmHg) 78±3 87±12* 91±14**
Glucose (mgdl 1) 84±9 95±22* 100±23**
Insulin (Uml 1) 7±4 20±23* 29±26**
HOMA-IR 1.5±1.0 5.3±9.6* 8.0±10.5*
Triglycerides (mgdl 1) 95±59 125±65* 138±94
HDL (mgdl 1) 67±18 52±15** 50±14**
LDL (mgdl 1) 116±25 121±29 124±29
Leptin (mg l 1) 10±10 51±35** 59±40**
Adiponectin (mgml 1) 13.7±10.4 9.3±3.3** 9.0±4.6**
hsCRP (mg l 1) 1.5±2.1 5.5±6.1* 8.2±7.7**
TNF-a (pgml 1) 8.8±3.3 9.7±4.8 10.4±4.3
Hypertension (%) 17 41** 63**,w
Type 2 diabetes (%) 0 4 6
Dyslipidemia (%) 8 57** 48**
MetS (%) 0 48** 50**
ASA (%) 0 7* 10*
RAAS-I (%) 0 15** 14**
B-blocker (%) 0 9* 6*
Diuretics (%) 0 7* 8*
Abbreviations: ASA, acetylsalicylic acid; BMI, body mass index; BP, blood
pressure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model
assessment index; HsCRP, high-sensitivity C-reactive protein; LDL,
low-density lipoprotein; LVDD, left ventricular diastolic dysfunction; MetS,
metabolic syndrome; WHR, waist–hip ratio. *Po0.05, **Po0.01 vs control,
wPo0.05, wwPo0.01 vs obese, no LVDD (Tukey–Kramer test).
Table 2. Echocardiographic data, parameters of LVDD and exercise
capacity in normal weight controls, obese without and with LVDD
Control Obese, no LVDD Obese, LVDD
N 24 46 50
Epicardial fat (mm) 1.5±1.4 5.6±2.6** 8.0±4.3**,ww
LA diameter (mm) 34±8 38±7* 44±4**,ww
LA area (cm2) 14±3 18±4** 21±5**,ww
IVS (mm) 8.2±1.0 9.8±1.5** 11.7±2.0**,ww
PW (mm) 8.1±1.0 9.2±1.3** 10.9±1.5**,ww
RWT 0.33±0.04 0.37±0.06 0.42±0.07**,ww
LVEDD (mm) 47±4 51±5 52±6*
LVESD (mm) 29±4 31±4 33±5**
LVM (g) 172±41 236±71** 320±94**,ww
LVMi (gm 2) 97±18 102±18 128±27**,ww
EF (%) 69±7 65±6* 65±8*
E/A ratio 1.5±0.5 1.2±0.3* 1.2±0.4*
DT (ms) 213±47 198±42 221±82
IVRT (ms) 87±15 95±17 105±18**,ww
e0 (cm s 1) 16.5±5.8 14.7±3.7 10.8±3.9**,ww
E/e0 5.6±1.9 5.9±1.3 8.3±2.7**,ww
e0/a0 1.9±0.7 1.6±0.6 1.1±0.5**,ww
Tei index 0.55±0.10 0.62±0.17 0.62±0.13
S/D ratio 1.2±0.2 1.3±0.3 1.2±0.3
Ard (ms) 131±44 129±23 149±35*,w
Ard-ad (ms)  20±51  37±35  2±41ww
NT-proBNP (ng l 1) 45 (24–61) 38 (27–68) 52 (30–96)
GDF-15 (pgml 1) 452 (329–552) 443 (392–598) 565 (427–698)**,w
FABP4 (ngml 1) 13 (10–20) 34 (26–43)** 42 (32–53)**,w
6-min walk dist. (m) 686±103 570±87 555±94**,ww
Abbreviations: Ard, atrial systole flow; DT, deceleration time; E/A, ratio of
Early (E), late atrial (A) transmitral peak flow velocities; EF, ejection fraction;
FABP, fatty acid-binding protein; IVRT, isovolumetric relaxation time; IVS,
intravenous therapy; LA, left atrial; LVDD, left ventricular diastolic
dysfunction; LVEDD, left ventricular end-diastolic diameter; LVM, left
ventricular mass; NT-proBNP, N-terminal prohormone of brain natriuretic
peptide; PW, pulsed-wave Doppler; RWT, relative wall thickness; S/D,
systolic/diastolic ratio. *Po0.05, **Po0.01 vs control, wPo0.05, wwPo0.01 vs
obese, no LVDD (Tukey–Kramer test).
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hypertension and disturbed glucose metabolism. This may be
supported by the fact that in our study FABP4 levels were almost
identical in obese with and without LVDD, when the MetS was not
present.
In contrast, experimental evidence suggests that FABP4
released from human adipocytes potentially links obesity with
the development of myocardial contractile dysfunction. Speciﬁ-
cally, it has been recently demonstrated that mature human
adipocytes release FABP4 in the extracellular medium that
strongly suppress the contraction of cardiomyocytes by attenuat-
ing intracellular Ca2þ levels, suggesting a direct role in the
pathogenesis of myocardial dysfunction.11
Taking into consideration the accumulated evidence for FABP4
as a potential biomarker in systolic and diastolic HF, the crucial
question is whether this biomarker is really able to substantially
inﬂuence current clinical decision making or change the manage-
ment of HF patients, and whether it has better diagnostic or
prognostic accuracy (that is, higher clinical sensitivity) than current
prediction tools. In this regard, it needs to be demonstrated that
P <0.0001 P <0.0001
P <0.0001
P <0.0001 P =0.0001
P =0.0002
Figure 1. Association of increasing tertiles of FABP4 serum levels with epicardial fat thickness, parameters of LVDD and physical performance
(6-min walking distance). The figures illustrate both the means diamonds (dotted; the upper and lower edges span the 95% confidence
interval) and the box and whisper plots (representing the median, 25, 75, 10, and 90% quantiles) of each parameter.
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Figure 2. FABP4 serum levels in normal weight control subjects, in
metabolically healthy obese with or without LVDD, and in MetS obese
with and without LVDD. Data are displayed as least square means,
adjusted for age and sex±s.e. **Po0.01 LVDD vs normal LV function.
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increasing values of FABP4 are translated to higher mortality risk
in patients with HF, particularly in the obese. Therefore,
prospective outcome studies should be performed to elucidate
whether FABP4 also has prognostic impact on morbidity and
mortality in the obese.
Although we observed an increase of FABP4 levels in relation
to different degrees of LVDD, our results cannot be interpolated to
obese subjects with congestive HF. Thus, it would be interesting to
see the effect of therapeutical HF management on FABP4 levels in
these patients, that is, the effects of loop diuretics in congestive HF.
Moreover, the prospective study of serial measurements of FABP4
and its role in relation to considerable weight reduction on diastolic
function would reveal interesting future aims of the present study
cohort and may help validate FABP4 as a suitable biomarker.
Several limitations should be mentioned. First, the relatively
small sample size of our study poses a certain limitation; thus, our
results should be veriﬁed by more comprehensive studies. Second,
the present study is limited by its utilization of echocardiographic
techniques for the diagnosis of diastolic abnormalities. In fact,
most of the noninvasive parameters for assessment of LV diastolic
function by Doppler echocardiography are heart rate-, preload-
and afterload-dependent, and may vary over time in a given
patient. Moreover, because we studied very obese subjects,
echocardiographic measurements might be error-prone or impre-
cise. However, reliability analysis performed with interobserver
agreement statistics shows that concordance correlation for
Doppler measurements is reasonably good, thus allowing the
use of these measures in epidemiological studies.
In conclusion, we showed for the ﬁrst time that FABP4 serum
levels are positively associated with LVDD in morbidly obese
subjects with MetS.
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